Maxigen Biotech Inc. (1783.TW)
TWD 46.3
(-0.43%)
TWD 46.3
(-0.43%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -431.03 Million TWD | 45.5% |
| 2022 | -790.94 Million TWD | -57.07% |
| 2021 | -503.56 Million TWD | -154.8% |
| 2020 | -197.62 Million TWD | 21.87% |
| 2019 | -252.95 Million TWD | -991.08% |
| 2018 | 28.38 Million TWD | 116.96% |
| 2017 | -167.34 Million TWD | -108.78% |
| 2016 | -80.15 Million TWD | 63.83% |
| 2015 | -221.6 Million TWD | -784.57% |
| 2014 | 32.37 Million TWD | 114.14% |
| 2013 | -228.91 Million TWD | -214.06% |
| 2012 | -72.88 Million TWD | -33.69% |
| 2011 | -54.52 Million TWD | 79.55% |
| 2010 | -266.64 Million TWD | -50.29% |
| 2009 | -177.41 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -520.27 Million TWD | -7.7% |
| 2024 Q1 | -483.08 Million TWD | -12.08% |
| 2023 Q3 | -419.87 Million TWD | -4.19% |
| 2023 Q2 | -402.99 Million TWD | 51.55% |
| 2023 FY | -431.03 Million TWD | 45.5% |
| 2023 Q1 | -831.73 Million TWD | -5.16% |
| 2023 Q4 | -431.03 Million TWD | -2.66% |
| 2022 Q2 | -624.94 Million TWD | -11.68% |
| 2022 Q1 | -559.56 Million TWD | -11.12% |
| 2022 FY | -790.94 Million TWD | -57.07% |
| 2022 Q4 | -790.94 Million TWD | -11.07% |
| 2022 Q3 | -712.13 Million TWD | -13.95% |
| 2021 Q3 | -435.87 Million TWD | -120.08% |
| 2021 Q4 | -503.56 Million TWD | -15.53% |
| 2021 Q1 | -190.01 Million TWD | 3.85% |
| 2021 FY | -503.56 Million TWD | -154.8% |
| 2021 Q2 | -198.05 Million TWD | -4.23% |
| 2020 Q4 | -197.62 Million TWD | -45.09% |
| 2020 FY | -197.62 Million TWD | 21.87% |
| 2020 Q1 | -148.26 Million TWD | 41.38% |
| 2020 Q2 | -128.22 Million TWD | 13.52% |
| 2020 Q3 | -136.2 Million TWD | -6.22% |
| 2019 Q1 | -200.18 Million TWD | -807.59% |
| 2019 Q2 | -195.55 Million TWD | 2.31% |
| 2019 Q3 | -157.06 Million TWD | 19.68% |
| 2019 Q4 | -252.95 Million TWD | -61.05% |
| 2019 FY | -252.95 Million TWD | -991.08% |
| 2018 Q3 | -165.35 Million TWD | 1.7% |
| 2018 Q1 | -151.64 Million TWD | 9.38% |
| 2018 FY | 28.38 Million TWD | 116.96% |
| 2018 Q4 | 28.29 Million TWD | 117.11% |
| 2018 Q2 | -168.21 Million TWD | -10.93% |
| 2017 Q4 | -167.34 Million TWD | -31.67% |
| 2017 Q2 | -114.36 Million TWD | -47.98% |
| 2017 Q1 | -77.28 Million TWD | 3.57% |
| 2017 FY | -167.34 Million TWD | -108.78% |
| 2017 Q3 | -127.09 Million TWD | -11.13% |
| 2016 Q2 | -54.38 Million TWD | 32.56% |
| 2016 Q1 | -80.64 Million TWD | 63.61% |
| 2016 FY | -80.15 Million TWD | 63.83% |
| 2016 Q4 | -80.15 Million TWD | 5.56% |
| 2016 Q3 | -84.87 Million TWD | -56.05% |
| 2015 Q3 | -31.87 Million TWD | -72.62% |
| 2015 FY | -221.6 Million TWD | -784.57% |
| 2015 Q4 | -221.6 Million TWD | -595.15% |
| 2015 Q2 | -18.46 Million TWD | -167.88% |
| 2015 Q1 | 27.2 Million TWD | -15.96% |
| 2014 Q1 | 19.34 Million TWD | 108.45% |
| 2014 Q4 | 32.37 Million TWD | 50.39% |
| 2014 FY | 32.37 Million TWD | 114.14% |
| 2014 Q3 | 21.52 Million TWD | -3.89% |
| 2014 Q2 | 22.39 Million TWD | 15.75% |
| 2013 FY | -228.91 Million TWD | -214.06% |
| 2013 Q2 | 12.32 Million TWD | -93.45% |
| 2013 Q3 | 2.66 Million TWD | -78.36% |
| 2013 Q4 | -228.91 Million TWD | -8680.06% |
| 2013 Q1 | 188.22 Million TWD | 358.24% |
| 2012 Q4 | -72.88 Million TWD | 0.0% |
| 2012 FY | -72.88 Million TWD | -33.69% |
| 2012 Q2 | -44.27 Million TWD | 0.0% |
| 2011 Q2 | -60.82 Million TWD | 0.0% |
| 2011 Q4 | -54.52 Million TWD | 0.0% |
| 2011 FY | -54.52 Million TWD | 79.55% |
| 2010 Q4 | -266.64 Million TWD | 0.0% |
| 2010 FY | -266.64 Million TWD | -50.29% |
| 2009 FY | -177.41 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 227.48 Million TWD | 289.475% |
| SciVision Biotech Inc. | -163.18 Million TWD | -164.132% |
| Bionime Corporation | 2.42 Billion TWD | 117.772% |
| Pegavision Corporation | 63.52 Million TWD | 778.545% |
| Visco Vision Inc. | 563 Million TWD | 176.559% |